Literature DB >> 28161441

Apelin promotes mesenchymal stem cells survival and vascularization under hypoxic-ischemic condition in vitro involving the upregulation of vascular endothelial growth factor.

Jingying Hou1, Tingting Zhong1, Tianzhu Guo1, Changqing Miao2, Changqing Zhou1, Huibao Long1, Hao Wu1, Shaoxin Zheng3, Lei Wang1, Tong Wang4.   

Abstract

BACKGROUND: Mesenchymal stem cells (MSCs) transplantation has been regarded as an optimal therapeutic approach for cardiovascular disease. However, the inferior survival and low vascularization potential of these cells in the local infarct site reduce the therapeutic efficacy. In this study, we investigated the influence of apelin on MSCs survival and vascularization under hypoxic-ischemic condition in vitro and explored the relevant mechanism.
METHODS: MSCs were obtained from C57BL/6 mice and cultured in vitro. Cells of the third passage were divided into MSCs and MSCs+apelin groups. In the MSCs+apelin group, MSCs were stimulated with apelin-13 (5μM). The two groups experienced exposure to hypoxia (1% O2) and serum deprivation for 24h, using normoxia (20% O2) as a negative control during the process. Human umbilical vein endothelial cells (HUVECs) were used and incubated with conditioned media from both groups to promote vascularization for another 6h. Vascular densities were assessed and relevant biomarkers were detected thereafter.
RESULTS: Compared with MSCs group, MSCs+apelin group presented more rapid growth. The proliferation rate was much higher. Cells apoptosis percentage was significantly declined both under normoxic and hypoxic conditions. Media produced from MSCs+apelin group triggered HUVECs to form a larger number of vascular branches on matrigel. The expression and secretion of vascular endothelial growth factor (VEGF) were significantly increased.
CONCLUSION: Apelin could effectively promote MSCs survival and vascularization under hypoxic-ischemic condition in vitro, and this procedure was associated with the upregulation of VEGF. This study provides a new perspective for exploring novel approaches to enhance MSCs survival and vascularization potential.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Marrow mesenchymal stem cells; Putative receptor protein related to the angiotensin receptor AT1 endogenous ligand; Vascular endothelial growth factor; Vascularization

Mesh:

Substances:

Year:  2017        PMID: 28161441     DOI: 10.1016/j.yexmp.2017.01.015

Source DB:  PubMed          Journal:  Exp Mol Pathol        ISSN: 0014-4800            Impact factor:   3.362


  12 in total

Review 1.  Apelinergic System Structure and Function.

Authors:  Kyungsoo Shin; Calem Kenward; Jan K Rainey
Journal:  Compr Physiol       Date:  2017-12-12       Impact factor: 9.090

Review 2.  Nanoparticles Targeting the Molecular Pathways of Heart Remodeling and Regeneration.

Authors:  Diana Gonciar; Teodora Mocan; Lucia Agoston-Coldea
Journal:  Pharmaceutics       Date:  2022-03-26       Impact factor: 6.525

3.  Long noncoding RNA H19 upregulates vascular endothelial growth factor A to enhance mesenchymal stem cells survival and angiogenic capacity by inhibiting miR-199a-5p.

Authors:  Jingying Hou; Lingyun Wang; Quanhua Wu; Guanghui Zheng; Huibao Long; Hao Wu; Changqing Zhou; Tianzhu Guo; Tingting Zhong; Lei Wang; Xuxiang Chen; Tong Wang
Journal:  Stem Cell Res Ther       Date:  2018-04-19       Impact factor: 6.832

Review 4.  The Role of Apelin in Cardiovascular Diseases, Obesity and Cancer.

Authors:  Marta B Wysocka; Katarzyna Pietraszek-Gremplewicz; Dorota Nowak
Journal:  Front Physiol       Date:  2018-05-23       Impact factor: 4.566

Review 5.  Priming approaches to improve the efficacy of mesenchymal stromal cell-based therapies.

Authors:  Nádia de Cássia Noronha; Amanda Mizukami; Carolina Caliári-Oliveira; Juçara Gastaldi Cominal; José Lucas M Rocha; Dimas Tadeu Covas; Kamilla Swiech; Kelen C R Malmegrim
Journal:  Stem Cell Res Ther       Date:  2019-05-02       Impact factor: 6.832

6.  Follistatin-like 1 protects mesenchymal stem cells from hypoxic damage and enhances their therapeutic efficacy in a mouse myocardial infarction model.

Authors:  Han Shen; Guanghao Cui; Yanqiong Li; Wenxue Ye; Yimin Sun; Zihan Zhang; Jingjing Li; Guiying Xu; Xiansheng Zeng; Yanxia Zhang; Wencheng Zhang; Zan Huang; Weiqian Chen; Zhenya Shen
Journal:  Stem Cell Res Ther       Date:  2019-01-11       Impact factor: 6.832

7.  Mapping current research and identifying hotspots on mesenchymal stem cells in cardiovascular disease.

Authors:  Chan Chen; Yang Lou; Xin-Yi Li; Zheng-Tian Lv; Lu-Qiu Zhang; Wei Mao
Journal:  Stem Cell Res Ther       Date:  2020-11-25       Impact factor: 6.832

8.  ELABELA ameliorates hypoxic/ischemic-induced bone mesenchymal stem cell apoptosis via alleviation of mitochondrial dysfunction and activation of PI3K/AKT and ERK1/2 pathways.

Authors:  Jiaying Fu; Xuxiang Chen; Xin Liu; Daishi Xu; Huan Yang; Chaotao Zeng; Huibao Long; Changqing Zhou; Haidong Wu; Guanghui Zheng; Hao Wu; Wuming Wang; Tong Wang
Journal:  Stem Cell Res Ther       Date:  2020-12-14       Impact factor: 6.832

9.  Hypoxia preconditioning promotes cardiac stem cell survival and cardiogenic differentiation in vitro involving activation of the HIF-1α/apelin/APJ axis.

Authors:  Jingying Hou; Lei Wang; Huibao Long; Hao Wu; Quanhua Wu; Tingting Zhong; Xuxiang Chen; Changqing Zhou; Tianzhu Guo; Tong Wang
Journal:  Stem Cell Res Ther       Date:  2017-09-29       Impact factor: 6.832

10.  Downregulation of Interleukin-13 Receptor α2 Inhibits Angiogenic Formation Mediated by Chitinase 3-Like 1 in Late Atherosclerotic Lesions of apoE-/- Mice.

Authors:  Qi Xue; Lei Chen; Jianwu Yu; Kewang Sun; Lifang Ye; Jianlei Zheng
Journal:  Front Physiol       Date:  2021-07-19       Impact factor: 4.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.